What AIMneXt Co. does

AIMneXt Co. is a Seoul-based digital therapeutics company developing evidence-based software-based medical interventions. Its first commercial product, Somzz, is a digital therapeutic device for the treatment of insomnia, followed by a pipeline of candidates—Meltz, FreyaX, and additional upcoming products—targeting infertility, panic disorder, and atopic dermatitis. The core technology is a clinical R&D platform that integrates multi-disciplinary expertise: psychiatry specialists, clinical and cognitive psychology experts, data analysts, pharmacists, regulatory affairs professionals, and ICT engineers, producing software interventions designed to comply with FDA digital therapeutics approval guidelines for international market access.

The company's business model is B2B and sales-led, with revenue generated through partnerships with health insurers (subscription/recurring), hospitals (subscription/recurring), and pharmaceutical companies (licensing/royalties). It targets the Korean domestic market initially and is positioning for international expansion via FDA-aligned product development. Distribution runs through institutional partners rather than direct-to-consumer channels, and pricing is not publicly disclosed. On March 23, 2026, AIMneXt entered a four-party strategic MOU with SolDoc, AimMed, and TodakCare to establish a digital therapy-based integrated healthcare service model, indicating an emerging ecosystem-partnership distribution strategy alongside its core insurer/hospital/pharma channels.

Name

AIMneXt Co.

Legal name

AIMneXt Co.

Website

https://aimnext.co.kr

Company type

Private

Operating status

Operating

Short description

AIMneXt Co. is a Seoul-based digital therapeutics company developing evidence-based software interventions, starting with Somzz for insomnia, targeting insurers, hospitals, and pharmaceutical companies as primary B2B partners.

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)

akta.pro secondary industries

DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM), Women’s Health & Fertility Therapeutics (Digital) (HLACANAK)

Keywords

• Digital therapeutics
• Software medical devices
• Evidence-based healthcare
• Insomnia treatment software
• Clinical R&D platform

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Insurer partnerships: Revenue generation through partnerships with health insurance providers for digital therapeutic coverage
2. Hospital partnerships: Revenue from hospital partnerships for digital therapeutic solutions
3. Pharma partnerships: Revenue through pharmaceutical company partnerships for digital therapeutics integration

Go-to-market motion1 record

Core offering

AIMneXt Co. develops and commercializes evidence-based digital therapeutic software products that deliver non-drug, software-based interventions to patients. Its lead product, Somzz, is a digital therapeutic device for insomnia treatment launching in the Korean market, with pipeline candidates Meltz and FreyaX expanding into infertility, panic disorder, and atopic dermatitis. The company targets FDA digital therapeutics approval guidelines to support international market entry.

Product overview

AIMneXt develops a portfolio of evidence-based digital therapeutic software products for healthcare. The company started with Somzz for insomnia treatment and is expanding into additional therapeutic areas including infertility (난임), panic disorder (공황장애), and atopic dermatitis (아토피). The product portfolio follows FDA digital therapeutics approval guidelines and aims to serve both domestic Korean and international markets. Revenue models are based on partnerships with insurers, hospitals, and pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Brands

• Somzz: Digital therapeutic device for insomnia treatment.
• Meltz
• FreyaX
• Upcoming

Products and services

• Somzz Digital therapeutic device for treating insomnia. A non-drug, evidence-based software intervention designed for safe and effective treatment of insomnia patients, intended to be prescribed and administered via healthcare partners.
• Meltz Pipeline digital therapeutic candidate included in AIMneXt's portfolio of evidence-based software interventions for disease prevention and treatment.
• FreyaX Pipeline digital therapeutic candidate within AIMneXt's portfolio of evidence-based software interventions.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• SolDoccoreStrategic or Co-development Partner · 23 March 2026SolDoc, a non-face-to-face medical treatment solution company, signed a four-party strategic memorandum of understanding with AimNext, AimMed, and TodakCare to establish a digital therapy-based integrated healthcare service model and promote business cooperation among the four parties.
• AimMedcoreStrategic or Co-development Partner · 23 March 2026Part of the four-party strategic MOU signed to establish a digital therapy-based integrated healthcare service model; AimNext is collaborating with AimMed alongside SolDoc and TodakCare.
• TodakCarecoreStrategic or Co-development Partner · 23 March 2026Part of the four-party strategic MOU signed to establish a digital therapy-based integrated healthcare service model; TodakCare joins SolDoc, AimNext, and AimMed in this collaborative partnership.

Scale indicators1 record

Recent moves4 records

Expansion highlights5 records

Direct peers

• Click Therapeutics: Prescription digital therapeutics developer pursuing FDA software-as-a-medical-device clearances across mental health and chronic conditions, with pharma partnership licensing structures similar to AIMneXt's.
• Happify Health: Digital mental health platform offering evidence-based therapeutic software for anxiety and depression, competing with AIMneXt's insomnia and panic disorder indications via insurer and employer channels.
• Akili Interactive: Digital therapeutics company commercializing prescription software-based treatments (e.g., for ADHD and cognitive dysfunction) via FDA-cleared SaMD pathways, closely mirroring AIMneXt's regulatory and commercial approach.
• CureApp: Japan-based digital therapeutics company developing prescription software medical devices, including for nicotine addiction and hypertension, with parallel SaMD regulatory pathway experience in Asia comparable to AIMneXt.
• Big Health: Developer of Sleepio, a digital therapeutic for insomnia. Most directly comparable to AIMneXt's Somzz product, operating in the same FDA-aligned DTx category targeting insurers, hospitals, and employers.
• Pear Therapeutics: Pioneer in prescription digital therapeutics with FDA-cleared products across substance use disorder, insomnia, and other indications, anchoring the DTx commercial and reimbursement model AIMneXt is targeting.
• Kaia Health: Digital therapeutics company focused on chronic pain and musculoskeletal conditions via evidence-based software interventions, operating a similar B2B partnership model with insurers and employers.
• Woebot Health: AI-driven conversational digital therapeutic for mental health, sharing AIMneXt's positioning of software-based, evidence-backed interventions that can integrate into care delivery and pharma pipelines.
• MindMaze: Developer of digital neurotherapeutics and rehabilitation software, sharing AIMneXt's combination of clinical evidence generation, prescription digital therapeutic positioning, and multi-indication CNS focus.

Broad incumbents

• Kakao Healthcare: Major Korean digital health platform from the Kakao ecosystem offering telemedicine and digital wellness, providing a broader incumbent benchmark for AIMneXt's Korean market positioning and partnership channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AIMneXt Co.